Represents Inyx's First Combination-Drug-Therapy Development NEW YORK, Nov. 29 /PRNewswire-FirstCall/ -- Inyx, Inc. (OTC Bulletin Board: IYXI) announced today that its wholly owned subsidiary, Inyx Pharma Limited, has been selected by a European pharmaceutical company to develop a combination between a corticosteroid and a beta-2-agonist in a single metered dose inhaler (MDI) utilizing a non-ozone-depleting hydrofluoroalkane (HFA) propellant. Corticosteroids are the most effective and widely used anti-inflammatory drugs for the treatment of bronchial asthma and other chronic obstructive pulmonary diseases (COPD), such as bronchitis and emphysema. They are often taken with short-acting or long-acting bronchodilators (beta-2-agonists) that are the primary rescue medicine used to treat asthma and other COPD attacks. Today, more and more physicians are prescribing for chronic asthma sufferers combination therapy as a regular drug regimen. Jack Kachkar, M.D., Chairman and CEO of Inyx, Inc., said, "We are very pleased that Inyx has been selected for this client's important HFA program. This represents Inyx's first combination drug-MDI development work for a client." Inyx is initially developing test batches in different dosages for the client. This will be followed by stability testing, which is targeted for mid-2006. Commercial production is aimed for 2007. "Being able to deliver corticosteroid and beta-2-agonist in a single inhaler will not only mean added convenience but also should provide cost savings to consumers because it eliminates the need for buying and carrying two separate inhalers, which should make this a strong competitive product. Moreover, by using a HFA propellant, our client will be able to market this combination therapy throughout Europe," added Dr. Kachkar. The European Union has banned the use of the ozone-depleting CFC (chlorofluorocarbon) propellant in pharmaceutical products, and the U.S. is starting to implement this ban. About Inyx Inyx, Inc. is a specialty pharmaceutical company with niche drug delivery technologies and products for the treatment of respiratory, allergy, dermatological, topical and cardiovascular conditions. Inyx focuses its expertise on both prescription and over-the-counter pharmaceutical products, and provides specialty pharmaceutical development and production consulting services to the international healthcare market. In addition, Inyx is developing its own proprietary products to be marketed by selected clients and strategic partners, which include some of the largest pharmaceutical companies. The company's operations are conducted through several wholly owned subsidiaries: Inyx USA, Ltd in Manati, Puerto Rico; Inyx Pharma Limited and Inyx Europe Limited, both near Manchester, England; Inyx Canada, Inc. based in Toronto, and Exaeris, Inc., based in Exton, Pennsylvania, which conducts Inyx's collaborative marketing and commercial development activities. Inyx, Inc.'s corporate offices are in New York City. For more information, please visit: http://www.inyxinc.com/. Safe Harbor Statements about the Inyx's future expectations, including future revenues and earnings, and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. Inyx intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, Inyx's actual results could differ materially from expected results. For more information, please contact: Jay M. Green, Executive Vice President Inyx, Inc. DATASOURCE: Inyx, Inc. CONTACT: Jay M. Green, Executive Vice President of Inyx, Inc., Web site: http://www.inyxinc.com/

Copyright